AIM: To investigate the therapeutic effect of Lucentis in the treatment of anterior segment neovascularization(ASNV)induced by central retinal vein occlusion(CRVO).

METHODS: This was a retrospective case series study for patients with ASNV secondary to CRVO from January 2013 to December 2014 and treated with intravitreal injection of lucentis. Best visual acuity(BCVA), intraocular pressure(IOP), iris examination and gonioscopy, and if necessary, fluorescein angiography and optical coherence tomography, were recorded. The follow-up time was 6-13mo, the average was 9.1±2.9mo.

RESULTS: Eighteen patients(18 eyes)were treated with intravitreal injection of lucentis; 15 patients(15 eyes)of the 18 were treated with panretinal photocoagulation; the other 3 patients 3 eyes were not received the photocoagulation because of vitreous opacity. One patient was treated with glaucoma valve implantation. Six patients with only neovascularization and without glaucoma were improved in visual acuity whose intraocular pressure was controlled after combined treatment. Of the patients with neovascular glaucoma(n=12), after intravitreal injection of lucentis and panretinal photocoagulation, the IOP was controlled in 4 patients(4 eyes); the IOP of another 7 cases reduced but glaucoma drugs were still needed. One patient(1 eye)received glaucoma valve implantation because of bad control on IOP with worse vision after implantation.The rubeosis disappeared in all patients.

CONCLUSION:Intravitreal injection of lucentis can stop neovascularization and help to control IOP. In the early stage without neovascular glaucoma, lucentis has better effects, which means early detection and intervention are important.